(Q33649918)

28 July 2017

title

Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. (English)

1 reference

28 July 2017

1 reference

1 reference

Su Wei Wong

1

1 reference

28 July 2017

Kai Hung Tiong

2

1 reference

28 July 2017

Weng Yip Kong

3

1 reference

28 July 2017

Yuen Chee Yue

4

1 reference

28 July 2017

Choon Hooi Chua

5

1 reference

28 July 2017

Jae Ying Lim

6

1 reference

28 July 2017

Chai Yuin Lee

7

1 reference

28 July 2017

Sean I Quah

8

1 reference

28 July 2017

Cindy Fow

9

1 reference

28 July 2017

Cyril Chung

10

1 reference

28 July 2017

Irene So

11

1 reference

28 July 2017

Boon Shing Tan

12

1 reference

28 July 2017

Heng Lungh Choo

13

1 reference

28 July 2017

Rozita Rosli

14

1 reference

28 July 2017

Soon-Keng Cheong

15

1 reference

28 July 2017

Chee-Onn Leong

16

1 reference

28 July 2017

language of work or name

English

0 references

publication date

5 August 2010

1 reference

Breast Cancer Research and Treatment

28 July 2017

published in

1 reference

28 July 2017

volume

128

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

301-313

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Mutant p53 mediates survival of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

The molecular portraits of breast tumors are conserved across microarray platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Deconstructing the molecular portrait of basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

A gene signature-based approach identifies mTOR as a regulator of p73.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

E1A activates transcription of p73 and Noxa to induce apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

BRCA1 supports XIST RNA concentration on the inactive X chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Impact of basal-like breast carcinoma determination for a more specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

X chromosomal abnormalities in basal-like human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

The role of BRCA1 in the cellular response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Triple-negative/basal-like breast cancer: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Targeting the DNA repair defect of BRCA tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Synergistic effect of rapamycin and cisplatin in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1055-0

10.1007/S10549-010-1055-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1040661858

0 references

1 reference